Kazia Therapeutics Says Two Abstracts Highlighting Paxalisib Tumor And Immune Reprogramming Research Accepted For Poster Presentation At 2026 San Antonio Breast Cancer Symposium

Presentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming Activity

SYDNEY, Nov. 2, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that two abstracts highlighting new preclinical and translational research on paxalisib's differentiated biological activity and potential application across breast cancer settings have been accepted for poster presentation at this year's San Antonio Breast Cancer Symposium ("SABCS"), taking place on Dec. 8 through 11, 2026, in San Antonio, Texas.